Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: Inhibition of tumor growth and angiogenesis

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3603-3610

  Ranjan, Amalendu P ^a,b   Mukerjee, Anindita ^a,b   Helson, Lawrence ^c   Gupta, Rohan ^d   Vishwanatha, Jamboor K ^a,b  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c SignPath Pharma   (United States)

^d University of North Texas Health Science Center   (United States)

Author keywords

Annexin A2; Curcumin; Liposomal curcumin; MiaPaCa cells; Pancreatic cancer; Xenograft

Indexed keywords

CURCUMIN; LIPOCORTIN 2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANNEXIN A2; CURCUMIN; LIPOSOMAL CURCUMIN; MIAPACA CELLS; PANCREATIC CANCER; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CURCUMIN; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884994929     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Strimpakos A, Saif MW and Syrigos KN: Pancreatic cancer: From molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 27: 495-522, 2008.
3. Burris HA,3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
4. Sharma OP: Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 25: 1811-1812, 1976.
5. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN and Kuttan R: Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett 94: 79-83,1995.
6. Sugiyama Y, Kawakishi S and Osawa T: Involvement of the betadiketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem Pharmacol 52: 519-525, 1996.
7. Srimal RC and Dhawan BN: Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25: 447-452, 1973.
8. Jordan WC and Drew CR: Curcumin a natural herb with anti-HIV activity. J Natl Med Assoc 88: 333, 1996.
9. Mahady GB, Pendland SL, Yun G and Lu ZZ: Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res 22: 4179-4181, 2002.
10. Kim MK, Choi GJ and Lee HS: Fungicidal property of Curcuma longa L. rhizome-derived curcumin against phytopathogenic fungi in a greenhouse. J Agric Food Chem 51: 1578-1581, 2003.
11. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN: Curcumin for malaria therapy. Biochem Biophys Res Commun 326(2): 472-474, 2005.
12. Kuttan R, Bhanumathy P, Nirmala K and George MC: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 29: 197-202, 1985.
13. Kuo ML, Huang TS and Lin JK: Curcumin, an antioxidant and antitumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1317: 95-100, 1996.
14. Chen H, Zhang ZS, Zhang YL and Zhou DY: Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 19: 3675-3680, 1999.
15. Mehta K, Pantazis P, McQueen T and Aggarwal BB: Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 8: 470-481, 1997.
16. Li L, Braiteh FS and Kurzrock R: Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104: 1322-1331, 2005.
17. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999.
18. Yallapu MM, Gupta BK, Jaggi M and Chauhan SC: Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 351: 19-29, 2010.
19. Mukerjee A and Vishwanatha JK: Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 29: 3867-3875, 2009.
20. Brigger I, Dubernet C and Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651, 2002.
21. Patra D and Barakat C: Unique role of ionic liquid [bmin][BF4] during curcumin-surfactant association and micellization of cationic, anionic and non-ionic surfactant solutions. Spectrochim Acta Pt A 79: 1823-1828, 2011.
22. Thangapazham RL, Puri A, Tele S, Blumenthal R and Maheshwari RK: Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 32(5): 1119-1123, 2008.
23. Goethals EC, Elbaz A, Lopata AL, Bhargava SK and Bansal V: Decoupling the effects of the size, wall thickness, and porosity of curcumin-loaded chitosan nanocapsules on their anticancer efficacy: size is the winner. Langmuir 29: 658-666, 2013.
24. Yadav VR, Suresh S, Devi K and Yadav S: Novel formulation of solid lipid microparticles of curcumin for antiangiogenic and antiinflammatory activity for optimization of therapy of inflammatory bowel disease. J Pharm Pharmacol 61(3): 311-321, 2009.
25. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A and Maitra A: Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): A novel strategy for human cancer therapy. J Nanobiotechnology 5: 3, 2007.
26. Sahu A, Bora U, Kasoju N and Goswami P: Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomaterialia 4: 1752-1761, 2008.
27. Shaikh J, Ankola DD, Beniwal V, Singh D and Kumar MNVR: Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J of Pharmaceuti Sci 37: 223-230, 2009.
28. Patra D, El Khoury E, Ahmadieh D, Darwish S and Tafech RM: Effect of curcumin on liposome: Curcumin as a molecular probe for monitoring interaction of ionic liquids with 1,2-Dipalmitoylsn-Glycero-3-phosphocholine liposome. Photochem Photobiol 88: 317-327, 2012.
29. Sneharani AH, Karakkat JV, Singh SA and Rao AG: Interaction of curcumin with βeta-Lactoglobulin-stability, spectroscopic analysis, and molecular modeling of the complex. J Agric Food Chem 58: 11130-11139, 2010.
30. Li L, Ahmed B, Mehta K and Kurzrock R: Liposomal curcumin with and without oxaliplatin: Effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6: 1276-1282, 2007.
31. Mach CM, Mathew L, Mosley SA, Kurzrock R and Smith JA: Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res 29: 1895-1899, 2009.
32. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB and Sood AK: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13(11): 3423-3430, 2007.
33. Valapala M, Thamake SI and Vishwanatha JK: A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J Cell Sci 124: 1453-1464, 2011.
34. Gururaj AE, Belakavadi M, Venkatesh DA, Marme D and Salimath BP: Molecular mechanisms of antiangiogenic effect of curcumin. Biochem Biophys Res Commun 297: 934-942, 2002.
35. Hahm ER, Gho YS, Park S, Park C, Kim KW and Yang CH: Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. Biochem Biophys Res Commun 321: 337-344, 2004.